ACT-385781A for PAH pediatric patients
Phase 3
- Conditions
- Pulmonary arterial hypertension (PAH)
- Registration Number
- JPRN-jRCT2080222670
- Lead Sponsor
- Actelion Pharmaceuticals Japan Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Idiopathic PAH, Heritable PAH, PAH associated with CHD
Exclusion Criteria
Patients with respiratory and/or cardiovascular distress in need of emergency care, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method